Newron and Merck Serono broaden CNS collaboration
Milan – Italian drugmaker Newron Pharmaceuticals S.p.A. and Merck Serono have broadened the scope of their 5-year-old collaboration on CNS drugs. In addition to the Parkinson’s treatment safinamide, under the terms of a new agreement Newron will receive a development for license Merck’s two discontinued clinical compounds pruvanserin and sarizotan, which target serotonin or dopamine receptors. Merck said it will retain buy-back options for both compounds upon completion of Phase IIb proof-of-concept. In the event that Merck exercises these options, Newron will have the possibility of co-development.